Austin D J, Nowak R A, Stewart E A
Department of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, Brigham and Women's Hospital, Boston, Mass., USA.
Gynecol Obstet Invest. 1999;47(4):268-71. doi: 10.1159/000010120.
To assess the action of onapristone, a type I antiprogestin, on prolactin (PRL) production by explant cultures of leiomyoma and myometrium.
Explant cultures of myometrium and leiomyomas from 3 premenopausal women undergoing hysterectomy in the proliferative phase of the menstrual cycle.
PRL secretion measured by radioimmunoassay.
PRL secretion was decreased in leiomyomas by onapristone. There was no effect in the myometrium. There was no additional effect with the addition of the type II antiprogestin mifepristone (RU 486).
PRL production is suppressed in leiomyomas but not in myometrium after treatment with onapristone in vitro. This suppression may serve as a marker for the clinical effectiveness of agents used in the treatment of leiomyomas.
评估Ⅰ型抗孕激素奥那司酮对子宫肌瘤和平滑肌层外植体培养物催乳素（PRL）分泌的作用。
对3名处于月经周期增殖期、接受子宫切除术的绝经前女性的平滑肌层和子宫肌瘤进行外植体培养。
采用放射免疫分析法测定PRL分泌。
奥那司酮可降低子宫肌瘤中的PRL分泌。对平滑肌层无影响。添加Ⅱ型抗孕激素米非司酮（RU 486）无额外作用。
体外使用奥那司酮治疗后，子宫肌瘤中的PRL分泌受到抑制，而平滑肌层不受影响。这种抑制作用可能作为治疗子宫肌瘤药物临床疗效的一个指标。
